Cancer-associated thrombosis (CAT) is a condition in which relevance has been
increasingly recognised both for physicians that deal with venous thromboembolism (VTE) …

Venous thromboembolism is a major complication in cancer patients. The basis for the
strong association between cancer and thrombosis remains incompletely understood, and …

In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite
outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients …

Venous thromboembolism (VTE) remains a substantial clinical and health-economic burden
worldwide and effective anticoagulant treatment is necessary immediately after VTE is …

Cancer is a known hypercoagulable state that leads to an increased risk of venous
thromboembolism (VTE). Low molecular weight heparin remains the preferred anticoagulant …

Background: Standard therapy for cancer-associated venous thromboembolism (VTE) is low-
molecular-weight heparin. The use of direct oral anticoagulants for cancer-associated VTE …

Background Low-molecular-weight heparins (LMWH) are the drug of choice for treatment of
cancer-associated thrombosis (CAT), however non-vitamin K antagonist oral anticoagulants …

Background Direct oral anticoagulants (DOACs) are not recommended for venous
thromboembolism (VTE) treatment in patients with cancer because their safety and efficacy …

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is
a global survey of physicians' perceptions and practice in the management of venous …

Direct oral anticoagulants (DOACs) represent an attractive alternative to low-molecular-
weight heparins (LMWHs) for the long-term treatment of cancer-associated thrombosis (CT) …